In the last thirty years, HDACs and their inhibitors have become a subject of research for many drug discovery scientists. This research led to the development and FDA approval of five different HDAC inhibitors: vorinostat, panobinostat, belinostat, romidepsin, and, as of March 2024, givinostat (Figure ). The approved inhibitors are all indicated for hematological cancers, with the exception of givinostat, which was the first non-steroidal drug approved for the treatment of Duchenne muscular dystrophy (DMD). HDAC inhibitors have also been explored as potential antimalarial drugs. Human malaria is caused by six species of Plasmodium protozoa: P. falciparum, P. vivax, P. ovale curtisi, P. ovale wallikeri, P. malariae, and the zoonotic parasite P. knowlesi. Several HDAC isoforms have been discovered in P. falciparum, the most lethal malaria-causing parasite. These include the zinc-dependent PfHDAC1 (class I), as well as PfHDAC2 and PfHDAC3 (class II). Additionally, sirtuins such as PfSir2A and PfSir2B, which require NAD + as a cofactor, are classified as class III HDACs. Another unclassified HDAC, PF10_0232, also known as CD-helicase-DNA-binding protein 1 homolog (CHD1)